Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H306
UPID:
MMP27_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H306; Q6UWK6
Background:
Matrix metalloproteinase-27 (MMP-27), encoded by the gene with the accession number Q9H306, plays a crucial role in the degradation of extracellular matrix components, including fibronectin, laminin, gelatins, and collagens. This process is vital for tissue remodeling, wound healing, and angiogenesis.
Therapeutic significance:
Understanding the role of Matrix metalloproteinase-27 could open doors to potential therapeutic strategies. Its involvement in the breakdown of the extracellular matrix suggests a pivotal role in diseases characterized by excessive tissue remodeling.